KR20030036389A - Food materials for preventing dementia and foods using the same - Google Patents
Food materials for preventing dementia and foods using the same Download PDFInfo
- Publication number
- KR20030036389A KR20030036389A KR1020030018414A KR20030018414A KR20030036389A KR 20030036389 A KR20030036389 A KR 20030036389A KR 1020030018414 A KR1020030018414 A KR 1020030018414A KR 20030018414 A KR20030018414 A KR 20030018414A KR 20030036389 A KR20030036389 A KR 20030036389A
- Authority
- KR
- South Korea
- Prior art keywords
- dementia
- food material
- extract
- prevention
- food
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 51
- 239000000463 material Substances 0.000 title claims abstract description 36
- 235000013305 food Nutrition 0.000 title claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 230000006872 improvement Effects 0.000 claims abstract description 11
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000010865 sewage Substances 0.000 claims description 8
- 241000411851 herbal medicine Species 0.000 claims description 7
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 6
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 6
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 210000004958 brain cell Anatomy 0.000 abstract description 9
- 230000004913 activation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 244000111306 Torreya nucifera Species 0.000 abstract 1
- 235000006732 Torreya nucifera Nutrition 0.000 abstract 1
- 240000005592 Veronica officinalis Species 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 27
- 230000008569 process Effects 0.000 description 26
- 239000003814 drug Substances 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 238000009739 binding Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229960001231 choline Drugs 0.000 description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 8
- 239000012676 herbal extract Substances 0.000 description 8
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 244000111489 Gardenia augusta Species 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 102000017927 CHRM1 Human genes 0.000 description 3
- 101150073075 Chrm1 gene Proteins 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 241001572175 Gaza Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 244000265736 Nelumbo pentapetala Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 208000013677 cerebrovascular dementia Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- -1 far wind Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000006049 herbal material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-L 5-[(3-carboxylato-4-nitrophenyl)disulfanyl]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)[O-])=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C([O-])=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-L 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 244000104272 Bidens pilosa Species 0.000 description 1
- 235000010662 Bidens pilosa Nutrition 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 description 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 중추신경계의 퇴화방지에 관여하는 아세틸콜린에스테라제 저해 활성(acetylcholinesterase inhibition activity)을 나타내는 다양한 생약재 추출물을 이용하여 식품소재를 제조한 다음 이들 조성물을 전통한과를 비롯한 각종 식품의 제조 공정 중에 첨가함으로써 고령화 사회에서 고빈도로 발생하는 치매 관련 질환을 예방 및 개선하는 효과가 있는 기능성 한과와 어린이용 뇌세포 활성을 촉진하는 총명한과를 제조하는 방법에 관한 것이다.The present invention is prepared by using a variety of herbal extracts exhibiting acetylcholinesterase inhibition activity involved in the prevention of degeneration of the central nervous system using a variety of herbal extracts during the manufacturing process of various foods, including the traditional fruit The present invention relates to a method for producing functional confections that have the effect of preventing and ameliorating dementia-related diseases occurring in an aging society by adding them, and the intelligent fruits that promote brain cell activity for children.
치매란 의식이 청명한 상태에서 전반적인 인지기능의 장애를 나타내는 뇌질환으로 보통 만성 또는 진행성 뇌질환에 의해서 발생되며 기억, 사고 지남력, 이해, 계산, 학습, 언어 판단 등 다수의 고위 대뇌기능에 장애가 나타나는 증후군이다. 치매는 인간의 사망 우선 순위가 관상동맥질환, 암 다음으로 세계 3위에 해당될 정도로 흔한 질병이다. 전 세계적으로는 2천5백만명 정도가 이 질병에 시달리고 있으며, 우리나라에는 1960년에는 전체인구 2,500만명 중 노인 인구가 72만명으로 2.9%에 불과했지만 1990년에는 약 214만여명(5.0%), 1995년에는 약 250만여명(5.6%)으로 증가하였고 2000년 이후에는 전체 인구의 7∼8%까지 증가할 것으로 보아 본격적인 고령화 사회가 될 것으로 예측된다. 따라서 치매 환자의 수도 나이에 급격히 비례하여 증가하는데 65세 이상에서는 6∼8%이고, 85세 이상에서는 30%정도가 치매에 시달릴 것으로 예상된다.Dementia is a brain disorder that indicates a general cognitive impairment in a clear state of consciousness, usually caused by chronic or progressive brain disorders, and impaired in many senior cerebral functions such as memory, thinking ability, understanding, calculation, learning, and language judgment. to be. Dementia is the most common disease in which human deaths rank third in the world after coronary artery disease and cancer. Around 25 million people worldwide suffer from this disease.In 1960, out of a total of 25 million people, the elderly population was 720,000, 2.9%, but in 1990, about 2.12 million (5.0%), 1995 It is expected to become a full-fledged aging society as it has increased to about 2.5 million people (5.6%) and from 2000 to 7-8% of the total population. Therefore, the number of patients with dementia increases rapidly with age, with 6-8% of patients over 65 years old and 30% of patients over 85 years old.
치매의 유발 질환에는 아직까지 뚜렷한 치료법이 없는 노인성치매, 뇌혈관성치매, 픽(Pick)병, 크로츠펠트-제이콥(Creutzfeldt-jakob)병 및 파킨슨(Parkinson)병 등이 있고, 치료 가능한 경우로는 우울성 가성치매, 갑상선기능저하증, 정상압뇌수종, 당뇨병, 약물중독, 빈혈 그리고 비타민 결핍증 등으로 인해 발생하는 치매가 있다. 노인성치매는 구미에서는 성인치매의 50∼60%를 차지하는데, 심한 미만성 뇌위축과 뇌세포의 소실로 인하여 기억력과 지능이 감퇴되고 추상적 사고 판단 및 고등대뇌피질기능에 장애가 발생하며 때로는 성격장애, 불면, 망상, 행동장애 등의 증상을 나타내는 병증으로 전반적인 고등정신기능의 장애와 인격의 황폐화를 나타내는 대표적인 질환이다. 또한 뇌졸중 후나 혹은 뇌동맥경화에 의해 광범위한 뇌병변이 발생함으로 유발되는 뇌혈관성치매는 구미에 비해 동양에서 상대적으로 높게 발병되는 것으로 보고되고 있다.Dementia-induced diseases include senile dementia, cerebrovascular dementia, Pick's disease, Creutzfeldt-jakob's disease, and Parkinson's disease. Dementia, dementia, hypothyroidism, normal pressure hydrocephalus, diabetes, drug addiction, anemia and vitamin deficiency. Geriatric dementia accounts for 50 to 60% of adult dementia in the West, with severe diffuse brain atrophy and loss of brain cells, resulting in loss of memory and intelligence, impaired abstract thinking and high cortical function. It is a symptom showing delusion and behavioral disorders, and it is a representative disease showing disorder of higher mental function and desolation of personality. In addition, cerebral vascular dementia caused by extensive brain lesions after stroke or by cerebral atherosclerosis is reported to be relatively higher in the East than in Europe.
한의학에서는 경악전서(景岳全書)에서 치애라 하여 최초로 치매의 증상에 관하여 언급하였으며, 그 이후 석실비녹(石室秘錄), 변증기문(辨證奇聞) 등에서 이를 태병이라 칭하고 그 증상 및 치료법에 관하여 비교적 자세하게 기록하였는데 그 이전에는 전광증(癲狂症), 건망증(健忘症), 울증(鬱症), 담습(痰濕), 허로(虛勞) 등 치매와 유사한 서로 다른 병증에 포함하여 치매를 파악한 것으로 생각된다. 치료면에서는 현대 서양의학에서, 앞에서 언급한 치료 가능한 몇몇 치매를 제외하고는 아직 노인성치매, 픽(Pick)병 및 뇌혈관성치매 등은 정확한 원인을 규명하지 못함에 따라 원인치료 없이 단지 대증치료만을 시행하고 있는 실정이므로 치매는 치료보다는 예방차원에서 관리하는 것이 효과적이 방안이 될 수 있다.In Oriental Medicine, it was the first to refer to the symptoms of dementia in terms of dementia. Since then, it has been referred to as Seokbinbinok, dialectic, and so on in terms of symptoms and treatment. The records were relatively detailed. Before that, dementia was identified by including other symptoms similar to dementia such as mania, forgetfulness, depression, phlegm, and erosion. I think. In terms of treatment, with the exception of some of the aforementioned treatable dementia, senile dementia, pick disease, and cerebrovascular dementia have not been identified. Therefore, dementia may be more effective than preventive treatment.
치매 치료제로 많은 약물들이 연구되었으나 아직까지 뚜렷한 효과가 입증된 약물은 없다. 다만 이 질환에서 인지기능장애가 주로 대뇌 기저부의 콜린(choline)성 신경세포의 손상에 의해 기인된 것이라는 가설과 함께 여러 가지 기전을 갖는 콜린(choline)성 약물들이 개발되었고 일부에서는 다소간의 효과가 입증된 바 있다. 최근에는 수용체 특이성이 높고 반감기가 길며 투여방법이 간단한 도네페질(donepezil)이 개발되어 유럽과 미국에서 사용되고 있다. 또한 차세대 치료법으로 가능성이 있는 방법에는 여러 신경전달물질에 작용하는 약물의 병합치료, 신경성장요소 및 유전공학적 치료 등을 들 수 있다. 즉, 콜린(choline)성 신경세포 외에도 다양한 신경전달물질의 이상이나 뇌피질위축 등이 보고 됨에 따라 치매의 병리생태는 한 가지 신경전달 물질이나 뇌의 일부분에 국한된 것이 아니라 비특이적이면서 광범위한 뇌영역과 신경전달물질을 포함시키는 콜린(choline)성/ 세로토닌(serotonin)성, 콜린(choline)성/소마토스타틴(somatostatin)성 약물의 병합치료가 시도될 것으로 예측된다. 신경세포의 재생능력이 낮다는 것을 고려하여 최근에는 퇴행성 경과를 지연시키는 방법이 임상에 더 필요하다고 인식되고 있다. 이러한 역할을 하는 것의 하나가 신경 성장 요소인데, 이것은 동물실험에서 수술 후 발생하는 콜린(choline)성 신경세포의 변성을 보호하는 효과가 입증되었으며콜린(choline)성 신경세포의 성장, 재생 및 유지에 필수적인 단백질이다. 아직까지는 뇌에 직접 투여해야하는 방법상의 문제가 있으나 이런 문제점이 해결된다면 새로운 치료방법으로 주목받을 것으로 사료된다. 근래 치매를 일으키는 유전자가 21번 염색체에 존재한다는 것이 확인되었고, 중요한 신경계 병변의 하나인 베타-아미로이드(β-amyloid) 단백질의 유전자를 규명하려는 연구들이 활발하므로 이 질환에 대한 유전자 치료의 가능성을 제시한 바 있다.Many drugs have been studied for the treatment of dementia, but no drug has yet been proven effective. However, in addition to the hypothesis that cognitive dysfunction is mainly caused by damage to choline neurons at the base of the cerebral base, choline drugs with various mechanisms have been developed, and some have proven somewhat effective. There is a bar. Recently, donepezil, which has high receptor specificity, long half-life, and simple administration method, has been developed and used in Europe and the United States. In addition, possible methods for the next generation of therapies include a combination therapy of drugs acting on various neurotransmitters, nerve growth factors, and genetic engineering treatments. In other words, in addition to choline neurons, various neurotransmitter abnormalities and cerebral cortical atrophy have been reported, so the pathology of dementia is not limited to one neurotransmitter or part of the brain, but is specific to a wide range of brain regions and nerves. Combination therapy of choline / serotonin, choline / somatostatin-containing drugs with delivery agents is expected. Considering the low regenerative capacity of neurons, it has recently been recognized that clinical methods are needed to delay the degenerative process. One of these roles is the nerve growth factor, which has been shown to protect the degeneration of choline neurons that occur after surgery in animal experiments and to the growth, regeneration and maintenance of choline neurons. It is an essential protein. There is still a problem in the method to be administered directly to the brain, but if this problem is solved, it is expected to attract attention as a new treatment method. Recently, it has been confirmed that a gene causing dementia exists on chromosome 21, and studies to identify genes of beta-amyloid protein, one of the important neurological lesions, have been actively conducted to determine the possibility of gene therapy for the disease. I have suggested.
따라서 가장 합리적인 치매 예방 및 개선용 신소재는 뇌세포의 파괴와 노화를 지연시켜주고, 인지 기능을 회복시키며, 뇌세포를 보호하며 뇌세포의 재생을 촉진하는 약물이어야 하지만 모두 충족시켜 주는 의약품 또는 식품은 현재 없는 실정이다. 이에 환자의 증상과 원인에 따른 약물선택을 적절히 해야 하는데, 진료의사의 숙련도에 맡길 수밖에 없는 것이 현실이다. 현재 사용되고 있는 약제는 항정신성 약물(Antipsychotics), 항우울제(Anticepressant), 항불안제(Antianxiety), 항경련제(Anticonvulsant), 뇌기능개선제(Nootropics), 신경전달물질의 대사에 관여하는 효소 차단제(Enzyme blocker), 칼슘 차단제(Ca-blocker) 등이 사용되며 현재 비교적 확실한 치료 효과가 입증된 것은 콜린(choline) 신경계 작용제 중 아세틸콜린스테라제(acetylcholinesterase) 억제제가 있다. 기억력 장애는 알츠하이머병의 초기증상이며 대표적인 증상으로 이러한 기억력 장애는 아세틸콜린의 감소에 의한 것이라고 알려진 후 치매환자들의 뇌 이미지 형상화(Brain image study)를 통해서 자료를 수집한 결과 아세틸콜린 신경계의 퇴화가 심한 것에 착안한 치료과정으로 인해 개발된 약물들이다.Therefore, the most reasonable new material for preventing and improving dementia should be a drug that delays the destruction and aging of brain cells, restores cognitive function, protects brain cells and promotes the regeneration of brain cells. There is no current. Therefore, it is necessary to appropriately select the drug according to the symptoms and causes of the patient, but the reality is that it is left to the doctor's skill. Currently used drugs include antipsychotics (Antipsychotics), antidepressants (Annticepressant), antianxiety (Antianxiety), anticonvulsant (Anticonvulsant), brain stimulants (Nootropics), enzyme blockers involved in the metabolism of neurotransmitters (Enzyme blocker), Calcium blockers (Ca-blocker), etc. are used, and the present relatively proven therapeutic effect is the acetylcholinesterase inhibitor of choline nervous system agents. Memory impairment is an early symptom of Alzheimer's disease and is a representative symptom. This memory impairment is known to be due to the decrease of acetylcholine, and after data collected through brain image study of dementia patients, severe degeneration of acetylcholine nervous system These are drugs that have been developed because of the therapeutic process that is focused on.
상기와 같이 치매 치료용 의약품 개발이 성공되지 않은 실정에서 노인성 치매 관련 질환을 예방 및 개선하는 합리적인 방법 중의 하나는 운동, 감각, 지남력 장애를 방지 및 개선하는 식품소재, 집중력과 기억력 장애를 예방 및 개선하는 식품소재, 그리고 중추신경계의 퇴화방지에 활성이 있는 식품소재 등이 병용된 조성물을 개발한 다음 식품 중에 첨가하여 일정량을 섭취함으로써 그 효과를 발휘하는 것인데, 따라서 본 발명은 상기 요소, 즉 운동, 감각, 지남력, 집중력, 기억력, 중추신경계 퇴화방지 등에 활성이 있는 식품 신소재를 개발하여 그 소재를 병용하여 조성물을 조제한 다음 상기 요인들에 대한 종합적인 활성이 발휘되는 전통한과를 제조하는 방법에 관한 것이다.As described above, one of the rational methods for preventing and improving senile dementia-related diseases in the development of a medicinal treatment for dementia is preventing and improving food materials, concentration and memory disorders that prevent and improve motor, sensory, and mental disability. To develop a composition using a food material, and a food material that is active in preventing the degeneration of the central nervous system, and then added to the food to take effect by ingesting a certain amount, therefore the present invention is the above element, that is, exercise, The present invention relates to a method for producing traditional Korean foods, in which a new food material with active sensation, persistence, concentration, memory, and prevention of central nervous system is developed, the composition is prepared in combination with the material, and the overall activity of the above factors is exerted. .
본 발명의 목적은 중추신경계 퇴화방지에 효과가 인증된 생약재의 열수추출물을 이용한 식품소재를 제공하는 것이다.An object of the present invention is to provide a food material using the hot water extract of the herbal medicine certified to prevent degeneration of the central nervous system.
또한 본 발명은 상기 치매 관련 질환에 활성이 인정된 식품소재를 이용하여 치매 예방 및 개선용 기능성 한과의 제조방법을 제공하는 것을 목적으로 한다.In addition, an object of the present invention is to provide a method for producing dementia preventive and improved functional Korean using food ingredients that have been recognized as active in dementia-related diseases.
그리고 본 발명은 상기 식품소재에 뇌세포 활성을 촉진하는 조성물을 추가한 식품 소재 및 이를 이용한 어린이용 총명한과를 제조하는 방법을 제공하는 것을 목적으로 한다.And it is an object of the present invention to provide a food material and a method of manufacturing a children's intelligent fruit using the same food composition is added to the composition for promoting brain cell activity to the food material.
본 발명은 중추신경계 퇴화방지에 효과가 인증된 하수오·금은화·목단피·죽여·비자엽·천궁·치자의 열수추출물을 이용한 치매 예방 및 개선용 기능성 식품소재를 제조하는 방법과 상기 치매 관련 질환에 종합적인 기능이 발휘되도록 상기 식품소재를 다시 혼합한 조성물의 제조방법에 관한 것이다.The present invention is a method for producing functional food materials for preventing and improving dementia using hot water extracts of sewage, gold silver, bark skin, dead skin, beetle leaf, celestial organ and gardenia which have been certified to prevent degeneration of the central nervous system and the dementia-related diseases. It relates to a method for producing a composition of the food material is mixed again so as to demonstrate the functional function.
또한 본 발명은 치매 관련 질환에 활성이 인정된 상기 생약 식품소재를 이용하여 한과의 제조과정중에 상기 식품소재를 첨가함으로써 치매 예방 및 개선에 효과를 발휘하는 치매 예방 및 개선용 기능성 한과제조 및 각종 식품의 제조시에 상기 식품소재를 첨가함으로써 치매 예방 및 개선에 효과를 발휘하는 기능성 식품의 제조방법에 관한 것이다.In another aspect, the present invention by adding the food material during the manufacturing process of the Chinese medicine using the herbal food material that is recognized as active in dementia-related diseases, functional herbal manufacture and various foods for dementia prevention and improvement exhibiting an effect on the prevention and improvement of dementia It relates to a method for producing a functional food exhibiting an effect on the prevention and improvement of dementia by adding the food material at the time of manufacture.
이외에 본 발명은 상기 식품소재에 기억력과 뇌세포 활성을 촉진하는 총명탕에 사용되는 생약재인 백복신, 석창포, 원지의 추출물을 추가하여 제조된 식품소재 및 이를 이용하여 어린이용 총명한과를 제조하는 방법을 포함한다.In addition, the present invention includes a food material prepared by adding the extract of herbal medicine Baekboksin, Seokchangpo, Wonji, which is used for Chongmyeongtang, which promotes memory and brain cell activity, to the food material, and a method for preparing a children's smart fruit using the same. do.
본 발명의 상기 생약재 추출물들은 식품위생법상 또는 약재학적으로 허용가능한 보형재를 이용한 공지의 방법으로 건강식품소재 또는 기능성 식품소재화 되어 식품제조에 첨가시킬 수 있다.The herbal extracts of the present invention can be added to the food production or health food material or functional food material by a known method using a food hygiene method or pharmacologically acceptable prosthetics.
본 발명에 사용된 생약재 식품소재는 목적에 따라 여러 가지 제형(엑기스, 즙, 열수추출물, 분말, 과립, 분쇄)으로 첨가될 수 있다.The herbal food material used in the present invention may be added in various formulations (extract, juice, hot water extract, powder, granules, grinding) according to the purpose.
본 발명에서 지칭하는 한과는 현재 시판되는 모든 형태의 전통한과를 포함한다.The Chinese family referred to in the present invention includes all types of traditional family currently available on the market.
본 발명의 치매 예방 및 개선용 기능성 식품소재 및 이를 이용한 한과제조방법을 아래의 실시예 1 : 치매 예방 및 개선용 기능성 식품소재의 제조방법, 실시예 2 : 치매 예방 및 개선용 기능성 한과 제조방법, 실시예 3 : 어린이용 총명한과 제조방법에 의해 예시하며, 본 실시예가 본 발명을 한정하는 것으로 간주해서는 아니된다.Functional food material for the prevention and improvement of dementia of the present invention and a method of manufacturing a confectionery using the same Example 1 below: Manufacturing method of functional food material for prevention and improvement of dementia, Example 2: Functional Korean medicine manufacturing method for preventing and improving dementia, EXAMPLE 3 Illustrated by the intelligent and the manufacturing method for children, this Example should not be considered as limiting this invention.
실시예 1.치매 예방 및 개선용 식품소재의 제조방법 Example 1. Method of manufacturing food material for preventing and improving dementia
〈제 1 공정〉<The first process>
운동 및 감각기능 활성 소재인 저령·산약·인진·어성초·오가피·황기·공사인, 집중력과 기억력 활성 소재인 황련·황백·가자, 중추신경계 활성소재인 하수오·금은화·목단피·죽여·비자엽·천궁·치자, 그리고 항산화성 활성소재인 원방풍·사간·연자육·삼백초·복분자의 상기 소재 각각 100g을 물로 잘 세척한 후 각각 물 1500㎖를 넣어 95∼100℃에서 5시간 이상 추출한다.Medicinal materials of active and sensory functions such as aging, mountain chemicals, injin, eoseongcho, ogapi, astragalus, construction workers, concentration and memory active materials such as yellow lotus, yellow white, gaza, central nervous system active material sewage, gold silver flower, bark skin, killing, non-leaf leaf, 100g of the above materials of Cheongung, Gardenia, and anti-oxidative active materials, such as far wind, sand, lotus, baekseoncho, and bokbun, were thoroughly washed with water, and then 1500ml of water were extracted for 5 hours or longer at 95-100 ° C.
〈제 2 공정〉<The second process>
상기 열수추출물을 여과지(whatman No.3)로 여과하여 찌꺼기를 제거한 순수한 생약 열수추출액 800㎖를 각각 얻는다.The hot water extract was filtered through a filter paper (whatman No. 3) to obtain 800 ml of pure herbal hot water extract, each of which was freed from debris.
〈제 3 공정〉<The third process>
상기 여과된 각각의 생약 추출액을 감압농축기를 이용하여 60℃에서 완전히 농축하여 분말을 얻는다.Each filtered herbal extract is concentrated completely at 60 ° C. using a vacuum concentrator to obtain a powder.
〈제 4 공정〉<The fourth process>
상기 분말을 증류수로 0.005, 0.05, 0.5, 1.0㎎/㎖ 농도가 되게 희석하여제1공정에서 언급한 생약소재별 활성을 측정하여 치매 관련 활성이 검출되는가를 확인한다. 각 생약소재에 대한 다양한 생리활성의 결과는 표 1, 2, 3에서 제시된 것과 같이 우수한 치매 관련 활성을 나타낸다.Dilute the powder to a concentration of 0.005, 0.05, 0.5, 1.0 mg / ml with distilled water and measure the activity of each herbal material mentioned in the first step to determine whether dementia-related activity is detected. The results of various physiological activities for each herbal material show excellent dementia related activity as shown in Tables 1, 2 and 3.
〈제 5 공정〉<The fifth process>
제4공정에서 치매 관련 생리활성이 나타낸 결과를 기초로 저령, 산약, 인진, 어성초, 오가피, 황기, 공사인 각 40g, 황련 80g, 황백, 가자 각 50g, 하수오, 금은화, 목단피, 죽여, 비자엽, 천궁, 치자 각 40g, 그리고 원방풍, 사간, 연자육, 삼백초, 복분자 각 50g을 혼합하여 잘 세척한 생약소재 910g에 물 10ℓ를 넣어 95∼100℃에서 5시간 이상 열수추출한 다음 제2공정의 여과공정, 제3공정의 농축공정을 거쳐 농축액 1200㎖(40Brix)를 얻는다.Based on the results of the dementia-related physiological activity in the fourth step, aging, potions, injin, eoseongcho, ogapi, astragalus, 40g each of construction workers, 80g of rhubarb, 50g each of Gaza, sewage, gold silver flower, bark skin, kill, non-leaf leaves 10 liters of water was added to 910 g of the Chinese herbal medicine material, cheongung, gardenia gardenia, each 40g, and 50g each of the original wind, sagan, lotus root, three hundred seconds, and bokbunja, followed by hot water extraction at 95 ~ 100 ℃ for 5 hours. The concentrated solution 1200ml (40Brix) is obtained through the 3rd process.
〈제 6 공정〉<The sixth process>
제5공정에서 제조된 농축액을 일부 동결건조하여 치매 관련 활성조사에 이용하고, 나머지는 치매예방 및 개선용 기능성 한과 제조에 활용한다. 이와 같이 제조된 동결건조품은 증류수로 0.005, 0.05, 0.5, 1.0㎎/㎖로 희석하여 치매 관련 활성을 측정하였을 때 표 4에서 보는 바와 같이 관련 활성이 높게 나타났다.The concentrated solution prepared in the fifth step is partially lyophilized and used for investigation of dementia-related activities, and the rest is used for the manufacture of functional Chinese medicine for preventing and improving dementia. The lyophilized product prepared as described above was found to have high related activity as shown in Table 4 when the dementia related activity was measured by diluting to 0.005, 0.05, 0.5, 1.0 mg / ml with distilled water.
표 1. 각 생약 추출물에 대한 글리신 결합 저해 활성(glycine binding site inhibition activity)Table 1. Glycine binding site inhibition activity for each herbal extract
표 2. 각 생약 추출물에 대한 무스카린 M1 수용체 결합 저해 활성(muscarin M1 receptor binding inhibition activity)Table 2. Muscarin M1 receptor binding inhibition activity for each herbal extract
표 3. 각 생약 추출물에 대한 아세틸콜린에스테라제 저해활성 (acetylcholinesterase inhibition actibity)Table 3. Acetylcholinesterase inhibition actibity for each herbal extract
표 4. 실시예 1의 제6공정의 생약 추출 조성물에 대한 치매 관련 활성Table 4. Dementia related activities of the herbal extract composition of the sixth step of Example 1
상기 표 1과 표 2의 결과는 글리신 결합저해(Glycine binding site inhibition)활성과 무스카린 엠1 수용체 결합 저해(Muscarine M1 receptor binding inhibition)활성에 대한 각 약물의 효과와 수용체-리간드의 상호관계를 연구하기 위하여 방사성 동위원소가 부착된 리간드를 사용하여 수용체와 반응시킨 후 유리섬유 필터(glass fiber filter)로 여과하는 과정을 거쳐 결합하지 않은 여분의 리간드를 제거한 뒤 세척된 필터 디스크(filter disc)에 잔존하는 동위원소의 양을 측정하여 수용체에 대한 리간드의 결합반응을 정량하고 이를 이용하여 약물의 효과를 결정하였다.The results of Table 1 and Table 2 study the effect of each drug on the glycine binding site inhibition (Mlycarine M1 receptor binding inhibition) activity and the relationship between the receptor-ligand In order to react with the receptor using a ligand attached to the radioisotope, the resultant is filtered through a glass fiber filter to remove the unbound extra ligand and then remains on the washed filter disc. The amount of the isotope was measured to quantify the binding reaction of the ligand to the receptor and to determine the effect of the drug.
본 발명을 위한 수용체 소스(source)로는 각 약물의 여러 서브타입(subtype)에 대한 상호작용을 제외시키기 위하여 CHO 세포에서 발현된 인간 재결합 무스카린 수용체 서브타입(human recombinant muscarin receptor subtype) 1과 2 (M1, M2)를 사용하였으며 글리신 결합(glycine binding site) 수용체는 쥐의 대뇌에서 분리한 수용체 분획을 사용하였다. 이들 수용체를 다량 함유한 세포분획은 냉동 보관한 뒤 최적의 농도로 희석하여 사용하였다.Receptor sources for the present invention include human recombinant muscarin receptor subtypes 1 and 2 expressed in CHO cells to exclude interactions with various subtypes of each drug. M 1 , M 2 ) and glycine binding site (glycine binding site) receptor was used as a fraction of the receptor isolated from the rat brain. Cell fractions containing large amounts of these receptors were stored frozen and diluted to the optimal concentration.
상기 표3의 아세틸콜린스테라제 (Acetylcholinesterase) 저해활성은 아세틸콜린(acetylcholine)에서 유리되어 나오는 다이오콜린(thiocholine)을 DTNB(5,5'-dithio bis-2-nitrobenzoate)와 반응시켜 얻은 생성물을 UV측정하여 활성을 계산하였다.Acetylcholinesterase inhibitory activity of Table 3 is obtained by reacting the product obtained by reacting thiocholine released from acetylcholine with DTNB (5,5'-dithio bis-2-nitrobenzoate). The activity was calculated by measuring.
즉, 글리신 결합저해(Glycine binding site inhibition)와 무스카린 엠1 수용체 결합 저해(Muscarine M1 receptor binding inhibition) 활성은 -70℃에 냉동 보관된 수용체 세포 분획을 각 실험을 위한 완충액으로 현탁시키고 단백질 함량을 바이오 래드 디씨 단백질 합성 키트(Bio-Rad DC Protein Assay Kit)로 확인한 후 각 수용체마다 최적의 농도로 조정하였다. 이때 수용체의 함량으로 대변되는 단백질 농도의 설정은 기초실험을 통하여 결정한 것이다. 모든 시험의 표본(sample)은 복제(duplicate)로 실험하였으며 실험에 필요한 완충액으로는 각 수용체가 최적의 조건으로 결합할 수 있는 각각의 완충액을 사용하였다. 그리고 반응의 최종 부피는 0.25㎖ 이었으며 여기에 50㎕의 핫-리간드(hot-ligand)와 10㎕의 시험약물이 포함되게 하였다. 반응의 시작은 100㎕의 수용체 현탁액(receptor suspension)을 첨가하는 것으로부터 하여 27℃에서 30-60분간 반응시켰다. 1단계 약효 검색에서는 두 농도 (1 μM, 10 μM)에 대하여 약물의 수용체에 대한 친화력을 검색하였다. 배양(Incubation)후 왈락 유리섬유 필터맷 지에프/씨(Wallac glass fiber filtermat GF/C)를 이용하여 이노테크 셀 하비스터 시스템(Inotech cell harvester system)으로 차가운 트리스(Tris) 완충액으로 여과하여 반응을 종료시키고 수용체에 결합된 동위원소를 분리한 후 세척하고 필터맷(filtermat)에 잔류하는 동위원소의 양을 마이크로베타-카운터(MicroBeta-Counter)로 측정하였다.In other words, glycine binding site inhibition and Muscarine M1 receptor binding inhibition activity were suspended in the buffer cell fractions stored at -70 ℃ in buffer for each experiment and the protein content was reduced. After confirming with the Bio-Rad DC Protein Assay Kit, it was adjusted to the optimal concentration for each receptor. At this time, the protein concentration represented by the content of the receptor is determined through the basic experiment. Samples of all tests were replicated and each buffer was used as the buffer required for the experiment. The final volume of the reaction was 0.25 ml, which contained 50 μl of hot-ligand and 10 μl of test drug. The reaction was started for 30-60 minutes at 27 ° C. by adding 100 μl of receptor suspension. In the first step drug search, the affinity of the drug for receptors was searched for two concentrations (1 μM and 10 μM). After incubation, the reaction was terminated by filtering with cold Tris buffer using an Inotech cell harvester system using a Wallac glass fiber filtermat GF / C. The isotope bound to the receptor was separated, washed, and the amount of isotope remaining in the filtermat was measured by a MicroBeta-Counter.
아세틸콜린스테라제(Acetylcholinesterase) 저해 활성실험에서, 효소활성은 엘만(Ellman) 방법에 따라 기질인 아세틸콜린(acetylcholine)이 가수분해되어 유리되어 나오는 다이오콜린(thiocholine)을 DTNB와 반응시켜 생성되는디다이오(dithio) 화합물과 니트로벤조산의 다이오(thio) 음이온을 UV로 검출하여 효소활성을 측정하였다. 이때 모든 반응은 1㎖ 큐벳(cuvette)에서 25℃로 고정시켜 30초와 60초 동안의 초기 속도를 측정하였고 효소저해활성은 기준반응에 대한 억제반응의 초기속도비로 환산하여 산출하였다.In the acetylcholinesterase inhibitory activity experiment, enzyme activity was produced by reacting thiocholine, which is released by hydrolysis of acetylcholine, which is a substrate, according to Elman's method with DTNB. Dithio compounds and nitrobenzoic acid thio anions were detected by UV to measure enzyme activity. At this time, all reactions were fixed at 25 ° C. in a 1 ml cuvette to measure initial rates for 30 seconds and 60 seconds, and enzyme inhibition activity was calculated in terms of the initial rate ratio of the inhibition reaction to the reference reaction.
실시예 2.치매 예방 및 개선용 기능성 한과 제조방법 Example 2. A functional Korean confectionery for preventing and improving dementia
〈제 1 공정〉<The first process>
선별된 찹쌀(65%)을 수용상에서 약 2주간 자연 발효시킨 다음 잘 세척하여 분쇄하여 미분말화 한다.Selected glutinous rice (65%) is naturally fermented in water for about 2 weeks, washed well and ground to fine powder.
〈제 2 공정〉<The second process>
찹쌀에 정종(1%), 생강즙(0.9%), 정제염(0.1%)을 첨가하여 잘 반죽한 후 100℃에서 증숙시킨다.Jeongjong (1%), ginger juice (0.9%), refined salt (0.1%) is added to the glutinous rice kneaded well and steamed at 100 ℃.
〈제 3 공정〉<The third process>
제 2 공정에서 증숙된 것을 방아에 넣어 줄이나도록 치면서 콩가루(19%)를 넣고 재차 치면서 반죽한다.Put steamed beans in the second process and add soy flour (19%) while striking to reduce the dough.
〈제 4 공정〉<The fourth process>
제3공정에서 반죽된 원료를 성형기에 넣고 성형시킨 후 27℃에서 수분 0.8%까지 건조시킨다.The raw material kneaded in the third step is put into a molding machine and then molded, and dried to 27% moisture at 27 ° C.
〈제 5 공정〉<The fifth process>
상기 건조된 원료를 대두유(2%)에 넣어 튀긴다.The dried raw material is fried in soybean oil (2%).
〈제 6 공정〉<The sixth process>
제5공정에 튀긴 한과를 실시예1의 제5공정에서 제조된 생약재 농축 조성물이 3∼15% 농도로 첨가된 물엿에 약 30초에서 1분간 침지시킨다.The confectionery fried in the fifth step is immersed in about 30 seconds to 1 minute in the syrup added to the herbal composition concentrated composition prepared in the fifth step of Example 1 at a concentration of 3 to 15%.
〈제 7 공정〉<The seventh process>
제6공정에서 생약재 농축조성물로 코팅된 한과에 백미 튀밥으로 옷을 입힌 후 자연건조한 다음 포장한다.In the sixth step, coat the Korean confectionery coated with the herbal composition concentrated with white rice, and then dry it and package it.
실시예 3.어린이용 총명한과 제조방법 Example 3 Smart Child Confectionery
〈제 1 공정〉<The first process>
동의보감의 처방인 총명탕의 생약재인 백복신 100g, 석창포 100g, 원지 100g에 하수오 100g과 산약 100g을 넣어 물로 잘 세척한 다음 물 5000㎖를 첨가하여 95∼100℃에서 5시간 이상 추출한 후 냉각한 다음 여과하여 순수한 생약 열수 추출물 2600㎖를 얻는다.Put 100g of sewage and 100g of sesame into 100g of Baeksin, 100g of Seokchangpo, 100g of raw paper, which is the herbal medicine of Donggibogam, and wash it well with water. Obtain 2600 ml of pure herbal hydrothermal extract.
〈제 2 공정〉<The second process>
제1공정에서 얻은 열수 추출물을 감압농축기로 농축하여 농축액 680㎖(40Brix)를 얻는다.The hydrothermal extract obtained in the first step is concentrated with a reduced pressure concentrator to obtain 680 ml (40 Brix) of concentrate.
〈제 3 공정〉<The third process>
선별된 찹쌀(65%)을 수용상에서 약 2주간 자연 발효시킨 다음 잘 세척하여 분쇄하여 미분말화 한다.Selected glutinous rice (65%) is naturally fermented in water for about 2 weeks, washed well and ground to fine powder.
〈제 4 공정〉<The fourth process>
찹쌀에 정종(1%), 생강즙(0.9%), 정제염(0.1%)을 첨가하여 잘 반죽한 후 100℃에서 증숙시킨다.Jeongjong (1%), ginger juice (0.9%), refined salt (0.1%) is added to the glutinous rice kneaded well and steamed at 100 ℃.
〈제 5 공정〉<The fifth process>
제 4 공정에서 증숙된 것을 방아에 넣어 줄이나도록 치면서 콩가루(19%)를 넣고 재차 치면서 반죽한다.Add steamed steam from the 4th process to the lanyard and beat soybean paste (19%) and knead again.
〈제 6 공정〉<The sixth process>
제5공정에서 반죽된 원료를 성형기에 넣고 성형시킨 후 27℃에서 수분 0.8%까지 건조시킨다.The raw material kneaded in the fifth step is put into a molding machine and then molded, and dried to 27% moisture at 27 ° C.
〈제 7 공정〉<The seventh process>
상기 건조된 원료를 대두유(2%)에 넣어 튀긴다.The dried raw material is fried in soybean oil (2%).
〈제 8 공정〉<The eighth process>
제7공정에 튀긴 한과를 제1공정에서 조제된 생약재 농축 조성물이 3∼20% 첨가된 물엿에 약 30초에서 1분간 침지시킨다.The confections fried in step 7 are dipped in starch syrup added with 3 to 20% of the herbal composition prepared in step 1 for about 30 seconds to 1 minute.
〈제 9 공정〉<The ninth process>
제8공정에서 생약재 농축조성물로 코팅된 한과에 백미 튀밥으로 옷을 입힌 후 자연건조한 다음 포장한다.In step 8, the Hanja coated with the herbal composition concentrate is dressed with white rice and rice, then dried naturally and packed.
본 발명은 치매 환자들에 있어서 중추신경계의 퇴화방지에 활성이 인증된 하수오·금은화·목단피·죽여·비자엽·천궁·치자의 열수추출물 또는 농축물을 단독 또는 혼합물을 제조하여 치매관련 질환 예방을 위한 식품소재로서 각종 식품 제조시에 사용할 수 있고, 특히 한과 제조공중 중에 첨가하여 제조함에 따라 이들 식품 또는 한과를 식이 함으로써 각종 치매 관련 질환의 예방과 개선을 가져올 수 있을 뿐만 아니라 향후 고령화 시대에 치매 환자 발생 빈도를 줄일 수 있다.The present invention provides a single or a mixture of sewage, gold and silver, bark skin, killing, non-leafed leaves, celery, and gardenia in the dementia patients, which is certified to prevent degeneration of the central nervous system. It can be used as a food material for the production of various foods, and in particular, by adding these ingredients in the Chinese medicine manufacturing industry, dieting these foods or Korean fruits can bring about prevention and improvement of various dementia-related diseases as well as dementia patients in the aging age. Frequency of occurrence can be reduced.
또한 본 발명은 동의보감의 총명탕의 사용 생약재인 백복신, 석창포, 원지 외에 본 발명에서 활성이 확인된 하수오와 산약을 첨가하여 얻어진 열수농축액을 한과 제조에 이용함으로써 뇌세포 활성을 촉진하는 기능성 식품인 어린이용 총명한과의 제조방법도 포함된다.In addition, the present invention is a functional food that promotes brain cell activity by using the hydrothermal concentrate obtained by the addition of sewage and acid powder confirmed in the present invention in addition to the herbal medicines Baekboksin, Seokchangpo, Wonji, which is the herbal medicine used in Dongbobogam. Also included is a method of making intelligent fruits.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030018414A KR20030036389A (en) | 2003-03-25 | 2003-03-25 | Food materials for preventing dementia and foods using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030018414A KR20030036389A (en) | 2003-03-25 | 2003-03-25 | Food materials for preventing dementia and foods using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2000-0048670A Division KR100456418B1 (en) | 2000-08-22 | 2000-08-22 | Food materials of glycine binding site inhibition activity, food materials for preventing dementia and foods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030036389A true KR20030036389A (en) | 2003-05-09 |
Family
ID=29578984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020030018414A KR20030036389A (en) | 2003-03-25 | 2003-03-25 | Food materials for preventing dementia and foods using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20030036389A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100700065B1 (en) * | 2004-04-20 | 2007-03-27 | 신준식 | A composition of chinese drugs having neuro-protecting activity |
| KR100720971B1 (en) * | 2004-06-11 | 2007-05-22 | 주식회사 유니젠 | Composition having Bamboo or Bamboo extract for androgen agonist |
| WO2013129772A1 (en) * | 2012-02-27 | 2013-09-06 | 국립생물자원관 | Pharmaceutical composition comprising nelumbo nucifera seed extract as active ingredient for protecting brain nerve cells |
| KR101341314B1 (en) * | 2012-04-20 | 2013-12-13 | 김무상 | Traditional korean sweets and method for manufacturing the same |
| KR102467787B1 (en) | 2022-04-27 | 2022-11-16 | 김규홍 | Methods for manufacturing compound feed using marine waste and manufacturing apparatus |
-
2003
- 2003-03-25 KR KR1020030018414A patent/KR20030036389A/en not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100700065B1 (en) * | 2004-04-20 | 2007-03-27 | 신준식 | A composition of chinese drugs having neuro-protecting activity |
| KR100720971B1 (en) * | 2004-06-11 | 2007-05-22 | 주식회사 유니젠 | Composition having Bamboo or Bamboo extract for androgen agonist |
| WO2013129772A1 (en) * | 2012-02-27 | 2013-09-06 | 국립생물자원관 | Pharmaceutical composition comprising nelumbo nucifera seed extract as active ingredient for protecting brain nerve cells |
| KR101341314B1 (en) * | 2012-04-20 | 2013-12-13 | 김무상 | Traditional korean sweets and method for manufacturing the same |
| KR102467787B1 (en) | 2022-04-27 | 2022-11-16 | 김규홍 | Methods for manufacturing compound feed using marine waste and manufacturing apparatus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100456418B1 (en) | Food materials of glycine binding site inhibition activity, food materials for preventing dementia and foods using the same | |
| KR100360674B1 (en) | Herbal composition for preventing and treating dementria | |
| CN106963820B (en) | Use of essential oil of pepper plant | |
| KR100382564B1 (en) | Herbal composition for prevention and treatment of alzheimer's disease | |
| CN107106624A (en) | Prevention, the composition for the mixed extract containing mulberries and fuling peel for improving or treating degenerative neural disease | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN100522193C (en) | Use of Broussonetia papyrifera red pigment | |
| JPH0725777A (en) | Synthesis promoter for neurotrophy factor | |
| CN109925402A (en) | A kind of Chinese medicine composition and the preparation method and application thereof | |
| KR20030036389A (en) | Food materials for preventing dementia and foods using the same | |
| JP6533294B2 (en) | Composition for prevention, amelioration or treatment of degenerative neurological disease containing scab extract | |
| KR100491429B1 (en) | Mixture of herbal extracts for memory enhancement | |
| CN113813310B (en) | Traditional Chinese medicine composition for preventing and treating brain diseases and preparation method and application thereof | |
| CN100462099C (en) | Composition for preventing and treating aphrenia | |
| KR100500029B1 (en) | Crude drug composition for promoting memory which contains Rehmanniae radix preparata extract | |
| KR102531387B1 (en) | Composition for improving of sleep disorder comprising Rhodiola rosea and seed of Nelumbo nucifera | |
| KR100526945B1 (en) | Dandelion anulus and process for preparing the same | |
| CN104435025A (en) | Novel use of broadleaf holly leaf in preparation of drugs for Alzheimer's disease | |
| CN112439077A (en) | Flavoring agent composition, preparation method and application thereof | |
| US20030003167A1 (en) | Herbal composition for the prevention and treatment of dementia | |
| KR102466377B1 (en) | Pharmaceutical composition for preventing or treating dry eye syndrome or degenerative brain disease comprising extracts of Papaver rhoeas or fractions thereof as an active ingredient | |
| KR102652533B1 (en) | Composition for preventing, improving, or treating depression or anxiety disorders containing mixed extracts | |
| CN107648374A (en) | A kind of Chinese medicine hepatoprotective composition, liver-protection traditional Chinese medicinal preparation and Chinese medicine liver-protecting tea | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR100526944B1 (en) | Dandelion granular tea and process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |